<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32788871</PMID><DateCompleted><Year>2021</Year><Month>06</Month><Day>21</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1449-1907</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>13</Issue><PubDate><Year>2020</Year></PubDate></JournalIssue><Title>International journal of medical sciences</Title><ISOAbbreviation>Int J Med Sci</ISOAbbreviation></Journal><ArticleTitle>Articulation recovery in ALS patients after lineage-negative adjuvant cell therapy - preliminary report.</ArticleTitle><Pagination><StartPage>1927</StartPage><EndPage>1935</EndPage><MedlinePgn>1927-1935</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7150/ijms.47002</ELocationID><Abstract><AbstractText><b>Background:</b> Amyotrophic lateral sclerosis (ALS) is one of the most frequently occurring neurodegenerative diseases affecting speech and swallowing. This preliminary study aimed to investigate whether an autologous lineage-negative stem/progenitor cell therapy applied to ALS patients affects the level of selected trophic and proinflammatory factors, and subsequently improves the articulation. <b>Methods:</b> We enrolled 12 patients with sporadic ALS, who underwent autologous bone marrow-derived lineage negative (LIN<sup>-</sup>) cells administration into cerebrospinal fluid (CSF). We evaluated patients' articulation using the Frenchay Dysarthria Assessment on days 0 and 28 following the LIN<sup>-</sup> cells administration. Concentrations of various factors (BDNF, NGF, ANGP-2, VEGF, PDGF-AA, PEDF, COMP-FH, CRP, C3, C4) in CSF were quantified by multiplex fluorescent bead-based immunoassays in the samples collected on the day of LIN<sup>-</sup> cells administration and 28 days later. On top of this, we assessed levels of BDNF and NGF in the patients' plasma on the day of the injection, three, seven days and three months after the treatment. <b>Results:</b> Of the 12 patients who received the LIN<sup>-</sup> cell therapy 8 showed short-termed improvement in articulatory functions (group I), which was particularly noticeable in better phonation time, lips and soft palate performance, swallowing reflex and voice loudness. Four patients (group II) did not show substantial improvement. CSF concentrations of BDNF, ANGP-2 and PDGF-AA in group I decreased significantly 28 days after LIN<sup>-</sup> cells administration. The highest concentration levels of BDNF in group II and NGF in both groups in blood plasma were observed on day 3 following the injection. <b>Conclusions:</b> The outcomes of the LIN<sup>-</sup> cell application in ALS treatment of articulatory organs are promising. The procedure proved to be safe and feasible. A short-lasting trophic effect of autologous LIN<sup>-</sup> administration could encourage repeated cell's application in order to sustain their beneficial effects, however this approach needs further investigation.</AbstractText><CopyrightInformation>&#xa9; The author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pawlukowska</LastName><ForeName>Wioletta</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumert</LastName><ForeName>Bart&#x142;omiej</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of General Pathology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Go&#x142;&#x105;b-Janowska</LastName><ForeName>Monika</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pius-Sadowska</LastName><ForeName>Ewa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of General Pathology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litwi&#x144;ska</LastName><ForeName>Zofia</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of General Pathology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kotowski</LastName><ForeName>Maciej</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Pathology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meller</LastName><ForeName>Agnieszka</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rotter</LastName><ForeName>Iwona</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Medical Rehabilitation and Clinical Physiotherapy, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peregud-Pogorzelski</LastName><ForeName>Jaros&#x142;aw</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Paediatric Oncology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nowacki</LastName><ForeName>Przemys&#x142;aw</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Pomeranian Medical University, Szczecin, Poland.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Int J Med Sci</MedlineTA><NlmUniqueID>101213954</NlmUniqueID><ISSNLinking>1449-1907</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009414">Nerve Growth Factors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="N">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019070" MajorTopicYN="N">Cell Lineage</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064987" MajorTopicYN="N">Cell- and Tissue-Based Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="N">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009414" MajorTopicYN="N">Nerve Growth Factors</DescriptorName><QualifierName UI="Q000134" MajorTopicYN="Y">cerebrospinal fluid</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LIN- stem/progenitor cells</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">dysarthria</Keyword><Keyword MajorTopicYN="N">neurotrophins</Keyword><Keyword MajorTopicYN="N">speech disorders</Keyword></KeywordList><CoiStatement>Competing Interests: The authors have declared that no competing interest exists.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>4</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>6</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>6</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32788871</ArticleId><ArticleId IdType="pmc">PMC7415387</ArticleId><ArticleId IdType="doi">10.7150/ijms.47002</ArticleId><ArticleId IdType="pii">ijmsv17p1927</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Haverkamp LJ, Appel V, Appel SH Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain. 1995;118:707&#x2013;719.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600088</ArticleId></ArticleIdList></Reference><Reference><Citation>Yorkston KM, Strand E, Miller R. et al. Speech deterioration in amyotrophic lateral sclerosis: implications for the timing of intervention. J Med Speech Lang Pathol. 1993;1:35&#x2013;46.</Citation></Reference><Reference><Citation>Netsell R, Lotz WK, Barlow SMA. Speech physiology examination for individuals with dysarthria. In: Yorkston K.M, Beukelman D.R, editors. Recent advances in dysarthria. MA: Little, Brown and Co. Boston. 1989. p:3-37.</Citation></Reference><Reference><Citation>Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst Rev.2012;3: CD001447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055506</ArticleId><ArticleId IdType="pubmed">22419278</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui LY, Liu MS, Tang XF. Single fibre electromyography in patients with amyotrophic lateral sclerosis. Chin Med J. 2004;117:1830&#x2013;1833.</Citation><ArticleIdList><ArticleId IdType="pubmed">15603713</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma A, Steele J. Botulinum toxin improves sialorrhoea and quality of living in bulbar amyotrophic lateral sclerosis. Muscle Nerve. 2006;34:235&#x2013;237.</Citation><ArticleIdList><ArticleId IdType="pubmed">16583370</ArticleId></ArticleIdList></Reference><Reference><Citation>Esposito SJ, Mitsumoto H, Shanks M. Use of palatal lift augmentation and palatal prostheses to improve dysarthria in patients with amyotrophic lateral sclerosis: a case series. J Prosthet Dent. 2000;83:90&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">10633027</ArticleId></ArticleIdList></Reference><Reference><Citation>Brownlee A, Palovcak M. The role of augmentative communication devices in the medical management of ALS. NeuroRehabilitation. 2007;22:445&#x2013;450.</Citation><ArticleIdList><ArticleId IdType="pubmed">18198430</ArticleId></ArticleIdList></Reference><Reference><Citation>Sellers EW, Vaughan TM, Wolpaw JR. A brain-computer interface for long-term independent home use. Amyotroph Lateral Scler. 2010;11:449&#x2013;455.</Citation><ArticleIdList><ArticleId IdType="pubmed">20583947</ArticleId></ArticleIdList></Reference><Reference><Citation>Machali&#x144;ski B, La&#x17c;ewski-Banaszak P, D&#x105;bkowska E, The role of neurotrophic factors in regeneration of the nervous system Neurol Neurochir Pol. 2012; 46:579-590.</Citation><ArticleIdList><ArticleId IdType="pubmed">23319226</ArticleId></ArticleIdList></Reference><Reference><Citation>Sobu&#x15b; A, Baumert B, Litwi&#x144;ska Z. et al. Safety and Feasibility of Lin- Cells Administration to ALS Patients: A Novel View on Humoral Factors and miRNA Profiles. Int J Mol Sci. 2018;27:1312.. pii: E1312. doi: 10.3390/ijms19051312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5983708</ArticleId><ArticleId IdType="pubmed">29702606</ArticleId></ArticleIdList></Reference><Reference><Citation>Silani V, Calzarossa C, Cova L. et al. Stem cells in amyotrophic lateral sclerosis: motor neuron protection or replacement? CNS Neurol Disord Drug Targets. 2010;9:314&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">20406179</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajivalili M, Pourgholi F, Kafil HS. et al. Mesenchymal Stem Cells in the Treatment of Amyotrophic Lateral Sclerosis. Curr Stem Cell Res Ther. 2016;11:41&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">26329483</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang DH, Lee HJ Park IH. et al. Intrathecal transplantation of human neural stem cells overexpressing VEGF provide behavioral improvement, disease onset delay and survival extension in transgenic ALS mice. Gene Ther. 2009;16:1234&#x2013;1244.</Citation><ArticleIdList><ArticleId IdType="pubmed">19626053</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper MM, Grozdanic SD, Blits B. et al. Transplantation of BDNF-secreting mesenchymal stem cells provides neuroprotection in chronically hypertensive rat eyes. Invest Ophthalmol Vis Sci. 2011;52:4506&#x2013;4515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175938</ArticleId><ArticleId IdType="pubmed">21498611</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilak MM, Corse AM, Kuncl RW. Additivity and potentation of IGF-1 and GDNF in the complete rescue of postnatal motor neurons. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001;2:83&#x2013;91.</Citation><ArticleIdList><ArticleId IdType="pubmed">11675876</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Wang F. Role of neuroinflammation in amyotrophic lateral sclerosis: Cellular mechanisms and therapeutic implications. Front. Immunol. 2017;8:1005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5567007</ArticleId><ArticleId IdType="pubmed">28871262</ArticleId></ArticleIdList></Reference><Reference><Citation>Diniz GP, Wang DZ. Regulation of skeletal muscle by microRNAs. Compr. Physiol. 2016;6:1279&#x2013;1294.</Citation><ArticleIdList><ArticleId IdType="pubmed">27347893</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganesalingam J, An J Shaw CE. et al. Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS. J. Neurochem. 2011;117:528&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3076545</ArticleId><ArticleId IdType="pubmed">21418221</ArticleId></ArticleIdList></Reference><Reference><Citation>Paczkowska E, Kaczynska K, Pius-Sadowska E. et al. Humoral activity of cord blood-derived stem/progenitor cells: Implications for stem cell-based adjuvant therapy of neurodegenerative disorders. PLoS One. 2013;8:e83833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3877125</ArticleId><ArticleId IdType="pubmed">24391835</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M. et al. El escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Mareschi K, Ferrero I, Rustichelli D. et al. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem. 2006;97:744&#x2013;754.</Citation><ArticleIdList><ArticleId IdType="pubmed">16229018</ArticleId></ArticleIdList></Reference><Reference><Citation>Enderby P, Palmer R. Frenchay Dysarthria Assessment 2 Edition (FDA-2) English. 2008.</Citation></Reference><Reference><Citation>Cymbaluk-Ploska A, Chudecka-Glaz A, Pius-Sadowska E. et al. Clinical relevance of NGAL/MMP-9 pathway in patients with endometrial cancer. Dis. Markers. 2017;2017:6589262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5635290</ArticleId><ArticleId IdType="pubmed">29089666</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomik B, Guiloff RJ. Dysarthria in amyotrophic lateral sclerosis: A review. Amyotrophic Lateral Sclerosis. 2010;11:4&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184513</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;rner S, Sieniawski M, Kollewe K. et al. Speech therapy and communication device: impact on quality of life and mood in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:20&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">22871079</ArticleId></ArticleIdList></Reference><Reference><Citation>Ball L, Beukelman D, Pattee G. Communication effectiveness of individuals with amyotrophic lateral sclerosis. J Commun Disord. 2004;37:197&#x2013;215.</Citation><ArticleIdList><ArticleId IdType="pubmed">15063143</ArticleId></ArticleIdList></Reference><Reference><Citation>Machali&#x144;ska A, Lubi&#x144;ski W, Penkala K. Functional improvement of injured retina following the adjuvant stem cell-based therapy. Preliminary report. Klin. Oczna. 2011;113:117&#x2013;121.</Citation><ArticleIdList><ArticleId IdType="pubmed">21913438</ArticleId></ArticleIdList></Reference><Reference><Citation>Machali&#x144;ski B, Paczkowska E, Koziarska D. et al. Mobilization of human hematopoietic stem/progenitor-enriched CD34+ cells into peripheral blood during stress related to ischemic stroke. Folia Histochem. Cytobiol. 2006;44:97&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">16805134</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed RG. Stress and Immunological Aging. Curr Opin Behav Sci. 2019;28:38&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548512</ArticleId><ArticleId IdType="pubmed">31179376</ArticleId></ArticleIdList></Reference><Reference><Citation>Toussaint M, Boitano LJ, Gathot V. et al. Limits of effective cough-augmentation techniques in patients with neuromuscular disease. Respir Care. 2009;54:359&#x2013;366.</Citation><ArticleIdList><ArticleId IdType="pubmed">19245730</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiernan MC, Vucic S, Cheah BC. et al. Amyotrophic Lateral Sclerosis. Lancet Neurology. 2011;377:942&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">21296405</ArticleId></ArticleIdList></Reference><Reference><Citation>McCool FD. Global physiology and pathophysiology of cough: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:48&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">16428691</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavlov VA, Wang H, Czura CJ. et al. The cholinergic anti-inflammatory pathway: a missing link in neuroimmunomodulation. Mol Med. 2003;9:125&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1430829</ArticleId><ArticleId IdType="pubmed">14571320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciesler J, Sari Y. Neurotrophic peptides: Potential drugs for treatment of amyotrophic lateral sclerosis and alzheimer's disease. Open J. Neurosci. 2013;3:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686488</ArticleId><ArticleId IdType="pubmed">23795307</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrou P, Gothelf Y, Argov Z. et al. Safety and clinical effects of mesenchymal stem cells secreting neurotrophic factor transplantation in patients with amyotrophic lateral sclerosis: Results of phase 1/2 and 2a clinical trials. JAMA Neurol. 2016;73:337&#x2013;344.</Citation><ArticleIdList><ArticleId IdType="pubmed">26751635</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartus RT, Johnson EM Jr. Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 1: Where have we been and what have we learned? Neurobiol. Dis. 2016;97:156&#x2013;168.</Citation><ArticleIdList><ArticleId IdType="pubmed">27063798</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim KS, Lee HJ, An J. et al. Transplantation of human adipose tissue-derived stem cells delays clinical onset and prolongs life span in ALS mouse model. Cell Transplant. 2014;23(12):1585&#x2013;1597.</Citation><ArticleIdList><ArticleId IdType="pubmed">24070071</ArticleId></ArticleIdList></Reference><Reference><Citation>Dadon-Nachum M, Ben-Yaacov K, Ben-Zur T. et al. Transplanted modified muscle progenitor cells expressing a mixture of neurotrophic factors delay disease onset and enhance survival in the SOD1 mouse model of ALS. J Mol Neurosci. 2015;55(3):788&#x2013;797.</Citation><ArticleIdList><ArticleId IdType="pubmed">25330859</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomsen GM, Avalos P, Ma AA. Transplantation of Neural Progenitor Cells Expressing Glial Cell Line-Derived Neurotrophic Factor into the Motor Cortex as a Strategy to Treat Amyotrophic Lateral Sclerosis. Stem Cells. 2018;36(7):1122&#x2013;1131.</Citation><ArticleIdList><ArticleId IdType="pubmed">29656478</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlukowska W, Baumert B, Go&#x142;&#x105;b-Janowska M. Influence of Lineage-Negative Stem Cell Therapy on Articulatory Functions in ALS Patients. Stem Cells Int. 2019. p:7213854. doi: 10.1155/2019/7213854.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6589318</ArticleId><ArticleId IdType="pubmed">31281384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>